Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649

医学 无容量 内科学 化疗 肿瘤科 化疗方案 食管癌 总体生存率 外科 护理标准 胃食管交界处
作者
Y. Y. Janjigian,Kouhei Shitara,J.A. Ajani,Lin Shen,Marcelo Garrido S,C. Gallardo,L.S. Wyrwicz,K. Yamaguchi,James M. Cleary,Elena C. Elimova,Ricardo Elias Bruges,M. V. Karamouzis,T SKOCZYLAS,A. Bragagnoli,T. Liu,Mustapha Ali Tehfe,Thomas Zander,Rubén Dario Kowalyszyn,Roberto Pazo-Cid,M. Schenker
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:37 (6): 787-797 被引量:38
标识
DOI:10.1016/j.annonc.2026.02.003
摘要

BACKGROUND: We report efficacy and safety results from the CheckMate 649 trial after 5 years of follow-up. PATIENTS AND METHODS: Adults with previously untreated, non-human epidermal growth factor receptor 2-positive, unresectable, advanced or metastatic gastroesophageal adenocarcinoma were randomized to receive nivolumab plus chemotherapy (n = 789) or chemotherapy (n = 792). Primary endpoints were met and reported previously, with nivolumab plus chemotherapy demonstrating superior overall survival (OS) and progression-free survival (PFS) versus chemotherapy in patients with programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥5. RESULTS: With a minimum follow-up of 60.1 months, the OS benefit [hazard ratio (HR) 0.71, 95% confidence interval (CI) 0.61-0.81] and PFS benefit (HR 0.71, 95% CI 0.61-0.82) with nivolumab plus chemotherapy versus chemotherapy in patients with PD-L1 CPS ≥5 were sustained. Five-year OS and PFS rates were 16% versus 6% and 10% versus 6%, respectively. Objective response rate per blinded independent central review was 58% (95% CI 54% to 62%) versus 46% (95% CI 42% to 50%), and median duration of response was 8.5 months (95% CI 7.7-9.9 months) versus 6.9 months (95% CI 5.9-7.6 months), respectively. Survival and response benefits were also maintained in patients with PD-L1 CPS ≥1, patients with PD-L1 CPS ≥10, and all randomized patients. Grade 3/4 treatment-related adverse events occurred in 60% of patients receiving nivolumab plus chemotherapy and 45% of patients receiving chemotherapy. No new safety concerns were observed. CONCLUSIONS: To our knowledge, these are the first reported 5-year results of a programmed cell death protein 1 inhibitor plus chemotherapy in gastroesophageal adenocarcinoma. Nivolumab plus chemotherapy continued to demonstrate long-term survival benefit and acceptable safety after 5 years of follow-up, reinforcing its use as a standard first-line treatment for PD-L1-positive patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
kio完成签到,获得积分10
刚刚
1秒前
dreamM完成签到,获得积分10
1秒前
1秒前
2秒前
科研通AI6.2的应助被匆匆采纳,获得10
2秒前
深情安青的应助被eating采纳,获得10
3秒前
3秒前
愉快的丹彤完成签到 ,获得积分10
3秒前
yyyyy发布了新的文献求助10
4秒前
4秒前
5秒前
zxd发布了新的文献求助10
5秒前
cdercder的应助被gong采纳,获得10
6秒前
6秒前
6秒前
张亚博发布了新的文献求助10
6秒前
7秒前
晴天完成签到 ,获得积分10
7秒前
多多发布了新的文献求助10
7秒前
鼻涕完成签到,获得积分10
7秒前
HDS发布了新的文献求助10
8秒前
8秒前
年年发布了新的文献求助10
9秒前
9秒前
9秒前
10秒前
无花果的应助被Q52采纳,获得10
10秒前
10秒前
11秒前
谎言不会伤人完成签到,获得积分10
12秒前
12秒前
YikC发布了新的文献求助10
13秒前
上官若男的应助被zxd采纳,获得10
13秒前
123发布了新的文献求助10
13秒前
yyyyy发布了新的文献求助10
13秒前
zyw发布了新的文献求助10
14秒前
14秒前
14秒前
南风发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193690
求助须知:如何正确求助?哪些是违规求助? 9579864
关于积分的说明 21868057
捐赠科研通 7793415
什么是DOI,文献DOI怎么找? 3437414
关于科研通互助平台的介绍 2560832
邀请新用户注册赠送积分活动 2484206